logo
Plus   Neg
Share
Email

Genentech: Tecentriq Fails To Meet Primary Endpoint In Phase III Study

Genentech, a member of the Roche Group (RHHBY), reported that the Phase III IMvigor010 study evaluating Tecentriq as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival compared to observation in people with muscle-invasive urothelial cancer.

Genentech noted that, in addition to ongoing Phase III studies in early and advanced bladder cancer, the company has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies across genitourinary, skin,
breast, gastrointestinal, gynecological and head and neck cancers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Deere & Co. (DE) reported that its net income attributable to the company for the first quarter grew to $517 million or $1.63 per share from $498 million or $1.54 per share in the prior-year quarter. Net sales and revenues for the quarter declined 4 percent to $7.63 billion from $7.98 billion in the... Tesla Inc. has received a German Court approval, allowing the electric car maker to continue to clear a forest area to build its Gigafactory in the country. A Berlin-Brandenburg court ruled that the company can continue to cut down trees at a forest site in Gruenheide. According to the court, local authorities have met legal requirements to allow early construction. Kolcraft Enterprises Inc. has recalled inclined sleeper accessory sold with certain sleepers to prevent suffocation risk, the U.S. Consumer Product Safety Commission said. The Chicago, Illinois-based company called back the products after reports of infant fatalities due to other manufacturers' inclined sleep products.
Follow RTT
>